RT Journal Article
SR Electronic
T1 Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.04.01.019877
DO 10.1101/2020.04.01.019877
A1 Zeng, Chunxi
A1 Hou, Xucheng
A1 Yan, Jingyue
A1 Zhang, Chengxiang
A1 Li, Wenqing
A1 Zhao, Weiyu
A1 Du, Shi
A1 Dong, Yizhou
YR 2020
UL http://biorxiv.org/content/early/2020/04/05/2020.04.01.019877.abstract
AB SARS-CoV-2 has rapidly become a pandemic worldwide; therefore, an effective vaccine is urgently needed. Recently, messenger RNAs (mRNAs) have emerged as a promising platform for vaccination. Here, we systematically investigated the untranslated regions (UTRs) of mRNAs in order to enhance protein production. Through a comprehensive analysis of endogenous gene expression and de novo design of UTRs, we identified the optimal combination of 5’ and 3’ UTR, termed as NASAR, which was five to ten-fold more efficient than the tested endogenous UTRs. More importantly, NASAR mRNAs delivered by lipid-derived nanoparticles showed dramatic expression of potential SARS-CoV-2 antigens both in vitro and in vivo. These NASAR mRNAs merit further development as alternative SARS-CoV-2 vaccines.